<DOC>
	<DOCNO>NCT01597674</DOCNO>
	<brief_summary>The objective study ass whether tolerance effect YF476 gastric pH observe repeated dos previous study healthy volunteer avoid use small dos YF476 .</brief_summary>
	<brief_title>Effect 5 , 10 25 mg YF476 Daily 14 Days Stomach Acidity Healthy Volunteers</brief_title>
	<detailed_description>YF476 novel , potent selective gastrin antagonist inhibits basal meal-stimulated gastric acid secretion , enhance gastric empty liquid meal increase low oesophageal sphincter pressure animal . In placebo- ranitidine-controlled , crossover study healthy volunteer , single dose 5 , 25 100mg YF476 increase gastric pH ; effect dose-dependent magnitude duration compare favourably ranitidine 150mg . In placebo- omeprazole-controlled , parallel-group study healthy volunteer , 25 100mg YF476 twice daily 7 day , significantly affect gastric pH unlike omeprazole 20mg daily 7 day . YF476 omeprazole increase plasma gastrin concentration . Single repeat dos YF476 well tolerate .</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Esophagitis , Peptic</mesh_term>
	<mesh_term>Gastrins</mesh_term>
	<criteria>Males age 1845 year . No clinically relevant abnormal finding clinical history physical examination screen assessment could interfere objective study make subject 's participation hazardous . No clinically relevant abnormal laboratory value screen evaluation ( Attachment 2 ) . A normal ECG screen examination . A body mass index ( Quetelet index ) range 19.030.9 : *Body Mass Index = weight [ kg ] _ height [ ] 2 Subjects must sufficient intelligence understand nature study hazard participation . They must able communicate satisfactorily Investigator participate , comply requirement , entire study . Subjects must give write consent participate reading InformationforVolunteers Leaflet Consent Form , opportunity discus study Investigator deputy . Clinically relevant abnormal history physical finding screen assessment , could interfere objective study safety subject 's participation . Clinically relevant abnormality laboratory value ECG screen evaluation . Presence acute chronic illness history chronic illness sufficient invalidate subject 's participation study make unnecessarily hazardous . Impaired endocrine , thyroid , hepatic , respiratory renal function , diabetes mellitus , coronary heart disease history psychotic mental illness . Participation clinical study new chemical entity prescription medicine within previous 3 month . Presence history drug alcohol abuse , intake 40 unit alcohol weekly . Loss 400mL blood 3 month study , e.g . blood donor . Use prescription medication 30 day study . Use overthecounter medicine 7 day study Blood pressure heart rate seat position screen examination outside range 90150mmHg systolic , 4090mmHg diastolic ; heart rate 40100 beats/min . Possibility subject cooperate requirement protocol . Evidence drug abuse urine test study entry . Positive test hepatitis B C HIV 1 &amp; 2 . High risk hepatitis HIV infection . History severe allergic disease .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>YF476</keyword>
	<keyword>gastrin receptor antagonist</keyword>
	<keyword>gastric pH</keyword>
	<keyword>gastrin</keyword>
	<keyword>healthy subject</keyword>
</DOC>